(NASDAQ: REVB) Revelation Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 9.68%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.82%.
Revelation Biosciences's earnings in 2025 is -$14,408,188.On average, 2 Wall Street analysts forecast REVB's earnings for 2025 to be -$4,560,485, with the lowest REVB earnings forecast at -$6,441,363, and the highest REVB earnings forecast at -$2,679,607. On average, 1 Wall Street analyst forecast REVB's earnings for 2026 to be -$1,869,955, with the lowest REVB earnings forecast at -$1,869,955, and the highest REVB earnings forecast at -$1,869,955.
In 2027, REVB is forecast to generate -$1,783,214 in earnings, with the lowest earnings forecast at -$1,783,214 and the highest earnings forecast at -$1,783,214.